Compare Novavax Inc (NVAX) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

TSLY trades at $21.57, down 0.74% today, with a bearish technical outlook indicated by moving averages and key indicators. The ETF generates substantial income through weekly distributions, with recent dividends ranging from $0.23 to $0.52 per share. However, the structure caps upside potential during Tesla rallies, as noted in recent analyst commentary.

While TSLY offers high yield potential through its option income strategy, investors face significant risks including capped upside capture, volatility exposure from Tesla's underlying performance, and potential return of capital distributions. The neutral sentiment from oscillators suggests limited near-term directional momentum.